| Autor: |
Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., Nahas, M. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p853-855, 3p |
| Abstrakt: |
B Introduction: b Patients with relapsed/refractory ( I R i / I R i ) follicular lymphoma (FL) experience progressively shorter remissions with each successive line of therapy, and the disease is largely considered incurable (Batlevi et al. I Blood Cancer J. i 2020). ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA However, outcomes of I R i / I R i FL have improved with the introduction of novel options including chimeric antigen receptor (CAR) T-cell therapy, a highly effective approach with potential to change the treatment paradigm (Jacobson et al. I Lancet Oncol. i 2021; Freedman, Jacobson. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text